title: A randomized cross-over comparison of two low-dose oral contraceptives upon hormonal and metabolic serum parameters: II. Effects upon thyroid function, gastrin, STH, and glucose tolerance.
abstract: The effect of a low-dose triphasic oral contraceptive (OC) containing ethinyl estradiol and levonorgestrel (EE/NG) upon thyroid function and some other biochemical serum parameters was compared to that of a preparation containing EE and desogestrel (EE/DG). Blood samples were taken on Day 6, 11, 21, and 28 of a control cycle and of the third cycle of treatment with either the EE/NG or EE/DG preparation (11 volunteers each). After a washout period of 3 months, the contraceptives were changed in a cross-over fashion. Blood samples were again taken on Day 6, 11, 21, and 28 of the third washout cycle and the third treatment cycle. There was a significant increase (13%) in basal glucose level during treatment with both OC, but no change in glucose tolerance. Both the EE/NG and FE/DG preparation elevated serum T4 (40%), FT4 (15-22%), T3 (17-28%), and TBG (20%) significant, whereby the effect was more pronounced during the second treatment period after washing-out. The effective thyroxine ratio (ETR) was slightly (4%) but significantly increased. Contrary to this, the levels of FT3, reverse T3 (rT3), TSH, and gastrin were not altered. STH showed great individual fluctuations, but was significantly elevated by 50% during treatment with both OC. There was no effect of endogenous estradiol upon thyroid or other parameter, even though it was raised considerably in some women under OC. Although the increase in T4 and T3 is probably due to a rise in estrogen-induced TBG production, the data seem to indicate that there is a slight but effective stimulation of thyroid function during treatment with low-dose OC.
authors.forename: H
authors.initials: H
authors.lastname: Kuhl
authors.forename: G
authors.initials: G
authors.lastname: Gahn
authors.forename: G
authors.initials: G
authors.lastname: Romberg
authors.forename: P H
authors.initials: PH
authors.lastname: Althoff
authors.forename: H D
authors.initials: HD
authors.lastname: Taubert
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000378:metabolism*; D003276:Contraceptives, Oral / Q000494:pharmacology*; D017135:Desogestrel; D004341:Drug Evaluation; D004997:Ethinyl Estradiol / Q000494:pharmacology; D019304:Ethinyl Estradiol-Norgestrel Combination; D005260:Female; D005755:Gastrins / Q000097:blood*; D013006:Growth Hormone / Q000097:blood*; D006801:Humans; D009644:Norgestrel / Q000494:pharmacology; D009652:Norpregnenes / Q000494:pharmacology; D011897:Random Allocation; D013961:Thyroid Gland / Q000187:drug effects* / Q000502:physiology; D013963:Thyroid Hormones / Q000097:blood
chemical_list: D001786:Blood Glucose; D003276:Contraceptives, Oral; D005755:Gastrins; D009652:Norpregnenes; D013963:Thyroid Hormones; D009644:Norgestrel; D004997:Ethinyl Estradiol; D019304:Ethinyl Estradiol-Norgestrel Combination; D017135:Desogestrel; D013006:Growth Hormone